Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • In vitro effects of vandetanib...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
In vitro effects of vandetanib on VEGFR2, EGFR and RET phosphorylation, endothelial cell tube formation, and tumor cell growth and survival

In vitro effects of vandetanib on VEGFR2, EGFR and RET phosphorylation, endothelial cell tube formation, and tumor cell growth and survival

Bibliographic Details
Main Authors: Brave, SR, Marshall, G, Wainwright, A, James, N, Acheson, N, Howard, Z, Ratcliffe, K, Speake, G, Barry, S, Hickinson, D, Ryan, A
Format: Journal article
Published: 2007
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
    by: Brave, SR, et al.
    Published: (2011)
  • A secondary RET mutation in the activation loop conferring resistance to vandetanib
    by: Takashi Nakaoku, et al.
    Published: (2018-02-01)
  • A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
    by: Pacey, S, et al.
    Published: (2016)
  • Deciphering the resistance mechanism of RET kinase mutant against vandetanib and nintedanib using molecular dynamics simulations
    by: Guodong Zheng, et al.
    Published: (2021-12-01)
  • Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
    by: Fallahi P, et al.
    Published: (2019-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs